当前位置: 首页 >> 检索结果
3145. Oral amoxicillin compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with fast breathing when referral is not possible: a randomised, open-label, equivalence trial.
作者: .;Antoinette Tshefu.;Adrien Lokangaka.;Serge Ngaima.;Cyril Engmann.;Fabian Esamai.;Peter Gisore.;Adejumoke Idowu Ayede.;Adegoke Gbadegesin Falade.;Ebunoluwa A Adejuyigbe.;Chineme Henry Anyabolu.;Robinson D Wammanda.;Clara L Ejembi.;William N Ogala.;Lu Gram.;Simon Cousens.
来源: Lancet. 2015年385卷9979期1758-1766页
WHO recommends referral to hospital for possible serious bacterial infection in young infants aged 0-59 days. We aimed to assess whether oral amoxicillin treatment for fast breathing, in the absence of other signs, is as efficacious as the combination of injectable procaine benzylpenicillin-gentamicin.
3147. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial.
作者: .;Antoinette Tshefu.;Adrien Lokangaka.;Serge Ngaima.;Cyril Engmann.;Fabian Esamai.;Peter Gisore.;Adejumoke Idowu Ayede.;Adegoke Gbadegesin Falade.;Ebunoluwa A Adejuyigbe.;Chineme Henry Anyabolu.;Robinson D Wammanda.;Clara L Ejembi.;William N Ogala.;Lu Gram.;Simon Cousens.
来源: Lancet. 2015年385卷9979期1767-1776页
WHO recommends hospital-based treatment for young infants aged 0-59 days with clinical signs of possible serious bacterial infection, but most families in resource-poor settings cannot accept referral. We aimed to assess whether use of simplified antibiotic regimens to treat young infants with clinical signs of severe infection was as efficacious as an injectable procaine benzylpenicillin-gentamicin combination for 7 days for situations in which hospital referral was not possible.
3148. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
作者: Christophe Hézode.;Tarik Asselah.;K Rajender Reddy.;Tarek Hassanein.;Marina Berenguer.;Katarzyna Fleischer-Stepniewska.;Patrick Marcellin.;Coleen Hall.;Gretja Schnell.;Tami Pilot-Matias.;Niloufar Mobashery.;Rebecca Redman.;Regis A Vilchez.;Stanislas Pol.
来源: Lancet. 2015年385卷9986期2502-9页
Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4 infection have low efficacy and poor tolerability, an unmet need exists for effective all-oral regimens. We examined the efficacy and safety of an all-oral interferon-free regimen of ombitasvir, an NS5A inhibitor, and paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (ombitasvir plus paritaprevir plus ritonavir), given with or without ribavirin.
3150. Hypertension.
Raised blood pressure is the biggest single contributor to the global burden of disease and to global mortality. The numbers of people affected and the prevalence of high blood pressure worldwide are expected to increase over the next decade. Preventive strategies are therefore urgently needed, especially in less developed countries, and management of hypertension must be optimised. Genetic advances in some rare causes of hypertension have been made lately, but the aggregate effect on blood pressure of all the genetic loci identified to date is small. Hence, intervention on key environmental determinants and effective implementation of trial-based therapies are needed. Three-drug combinations can control hypertension in about 90% of patients but only if resources allow identification of patients and drug delivery is affordable. Furthermore, assessment of optimal drug therapy for each ethnic group is needed.
3152. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial.
作者: Timothy M Cox.;Guillermo Drelichman.;Renata Cravo.;Manisha Balwani.;Thomas Andrew Burrow.;Ana Maria Martins.;Elena Lukina.;Barry Rosenbloom.;Leorah Ross.;Jennifer Angell.;Ana Cristina Puga.
来源: Lancet. 2015年385卷9985期2355-62页
The mainstay of treatment for Gaucher's disease type 1 is alternate-week infusion of enzyme replacement therapy (ERT). We investigated whether patients stable on such treatment would remain so after switching to oral eliglustat, a selective inhibitor of glucosylceramide synthase.
3155. Comparison of treatment of incomplete abortion with misoprostol by physicians and midwives at district level in Uganda: a randomised controlled equivalence trial.
作者: Marie Klingberg-Allvin.;Amanda Cleeve.;Susan Atuhairwe.;Nazarius Mbona Tumwesigye.;Elisabeth Faxelid.;Josaphat Byamugisha.;Kristina Gemzell-Danielsson.
来源: Lancet. 2015年385卷9985期2392-8页
Misoprostol is established for the treatment of incomplete abortion but has not been systematically assessed when provided by midwives at district level in a low-resource setting. We investigated the effectiveness and safety of midwives diagnosing and treating incomplete abortion with misoprostol, compared with physicians.
3159. Immediate delivery versus expectant monitoring for hypertensive disorders of pregnancy between 34 and 37 weeks of gestation (HYPITAT-II): an open-label, randomised controlled trial.
作者: Kim Broekhuijsen.;Gert-Jan van Baaren.;Maria G van Pampus.;Wessel Ganzevoort.;J Marko Sikkema.;Mallory D Woiski.;Martijn A Oudijk.;Kitty W M Bloemenkamp.;Hubertina C J Scheepers.;Henk A Bremer.;Robbert J P Rijnders.;Aren J van Loon.;Denise A M Perquin.;Jan M J Sporken.;Dimitri N M Papatsonis.;Marloes E van Huizen.;Corla B Vredevoogd.;Jozien T J Brons.;Mesrure Kaplan.;Anton H van Kaam.;Henk Groen.;Martina M Porath.;Paul P van den Berg.;Ben W J Mol.;Maureen T M Franssen.;Josje Langenveld.; .
来源: Lancet. 2015年385卷9986期2492-501页
There is little evidence to guide the management of women with hypertensive disorders in late preterm pregnancy. We investigated the effect of immediate delivery versus expectant monitoring on maternal and neonatal outcomes in such women.
3160. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial.
作者: Feng-Cai Zhu.;Li-Hua Hou.;Jing-Xin Li.;Shi-Po Wu.;Pei Liu.;Gui-Rong Zhang.;Yue-Mei Hu.;Fan-Yue Meng.;Jun-Jie Xu.;Rong Tang.;Jin-Long Zhang.;Wen-Juan Wang.;Lei Duan.;Kai Chu.;Qi Liang.;Jia-Lei Hu.;Li Luo.;Tao Zhu.;Jun-Zhi Wang.;Wei Chen.
来源: Lancet. 2015年385卷9984期2272-9页
Up to now, all tested Ebola virus vaccines have been based on the virus strain from the Zaire outbreak in 1976. We aimed to assess the safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine expressing the glycoprotein of the 2014 epidemic strain.
|